What is the preferred route of administration for epinephrine in the treatment of anaphylactic shock?
Which medication is the primary treatment for muscarinic effects in acute organophosphate poisoning?
The patient who developed a rash on the skin, hypotension, and difficulty in breathing after being given 2 g of ampicillin intravenously should be managed by.
Which of the following medications is contraindicated in head trauma patients?
Which of the following is an antagonist used to reverse the effects of benzodiazepines?
What is the drug of choice for managing status epilepticus?
Explanation: ***Intramuscular (IM)*** - **Intramuscular (IM)** injection is the preferred and fastest route for epinephrine in anaphylaxis due to its rapid absorption into the bloodstream. - Administering epinephrine IM into the **anterolateral aspect of the thigh** ensures quick systemic distribution to counteract the life-threatening symptoms. *Inhalational administration* - **Inhalational epinephrine** is not effective for systemic anaphylaxis, as it primarily targets the airways and does not provide sufficient systemic absorption or rapid cardiovascular support. - This route is typically reserved for localized bronchodilation and cannot reverse the widespread vasodilation and shock associated with anaphylaxis. *Subcutaneous route* - The **subcutaneous route** has a slower absorption rate compared to IM injection, which can delay the therapeutic effect of epinephrine during an acute anaphylactic reaction. - Delayed absorption can be critical in anaphylaxis, where rapid reversal of symptoms is necessary to prevent severe complications, including death. *Intravenous (IV)* - While **intravenous (IV)** epinephrine can be used in severe, refractory cases or in a hospital setting, it carries a higher risk of adverse cardiac events, such as arrhythmias or myocardial ischemia, especially if not carefully titrated. - For initial, pre-hospital management of anaphylaxis, the IM route is safer and more practical due to its rapid effect and lower risk profile compared to IV administration.
Explanation: ***Atropine*** - **Atropine** is a **muscarinic receptor antagonist** that directly blocks the effects of excessive acetylcholine at muscarinic sites, thereby reversing symptoms like bradycardia, bronchospasm, and excessive secretions seen in organophosphate poisoning. - It is the **primary agent** used to manage the muscarinic symptoms and is titrated until bronchorrhea and bronchospasm resolve. *Neostigmine* - **Neostigmine** is an **acetylcholinesterase inhibitor**, which would worsen the condition by increasing acetylcholine levels further. - It is used in conditions like **myasthenia gravis** to improve muscle strength, not in organophosphate poisoning. *Tubocurarine* - **Tubocurarine** is a **nicotinic receptor antagonist**, specifically a competitive neuromuscular blocker. - While organophosphate poisoning can affect nicotinic receptors, tubocurarine is not the primary treatment for muscarinic effects and could worsen respiratory depression in this context. *Pralidoxime* - **Pralidoxime** (2-PAM) is an **acetylcholinesterase reactivator** that can regenerate the enzyme, thereby reversing both muscarinic and nicotinic effects. - While crucial for reversing nicotinic effects and preventing 'aging' of the enzyme, it is **not the primary treatment for acute muscarinic crisis**; atropine is.
Explanation: ***0.5 ml of 1:1000 adrenaline by intramuscular injection*** - This presentation describes **anaphylaxis**, characterized by a rapid onset of rash, **hypotension**, and **difficulty breathing** following drug administration. - The immediate and definitive treatment for anaphylaxis is **intramuscular adrenaline (epinephrine)**, typically at a concentration of **1:1000** for rapid absorption and systemic effect. *0.5 ml of 1:1000 adrenaline by intravenous injection* - **Intravenous adrenaline** is generally reserved for patients who are unresponsive to intramuscular administration or are in **cardiac arrest**, as it carries a higher risk of adverse effects like arrhythmias. - The initial, first-line treatment in an evolving anaphylactic reaction should be **intramuscular injection** due to its safer profile and rapid onset of action. *0.5 ml of 1:10000 adrenaline by intramuscular injection* - A concentration of **1:10,000 adrenaline** is typically used for **intravenous administration** during advanced cardiac life support (ACLS) protocols, not for initial intramuscular injection in anaphylaxis. - Administering 1:10,000 adrenaline intramuscularly would provide a **suboptimal dose** for treating severe anaphylaxis effectively. *0.5 ml of 1:10000 adrenaline by intravenous injection* - While intravenous adrenaline uses a **1:10,000 concentration**, it's not the initial route for managing anaphylaxis unless the patient is in **cardiac arrest** or unresponsive to IM adrenaline. - Starting with IV adrenaline carries a higher risk of **cardiac complications** and can be difficult to administer promptly in an emergency outside of a controlled setting.
Explanation: ***Corticosteroids*** - While previously used, **corticosteroids** are now contraindicated in traumatic brain injury (TBI) due to evidence suggesting they may increase mortality. - **CRASH trial** showed that corticosteroids increased the risk of death in patients with head injury, possibly by exacerbating secondary brain injury. *Furosemide* - **Furosemide** can be used in certain situations to reduce intracranial pressure by inducing diuresis and reducing cerebral edema, especially when combined with mannitol. - It works by inhibiting the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, leading to increased water excretion. *Thiopentone* - **Thiopentone** (a barbiturate) can be used in severe head trauma to reduce cerebral metabolic rate, thereby decreasing cerebral blood flow and intracranial pressure. - It induces a **pharmacological coma** and provides neuroprotection by scavenging free radicals and stabilizing cell membranes. *Mannitol* - **Mannitol** is an osmotic diuretic commonly used to reduce intracranial pressure in head trauma by creating an osmotic gradient that draws water out of the brain parenchyma. - It is administered intravenously and works rapidly to decrease brain volume and improve cerebral perfusion pressure.
Explanation: ***Flumazenil*** - **Flumazenil** is a **competitive antagonist** at the **GABA-A receptor**, specifically binding to the benzodiazepine site. - By blocking benzodiazepines from binding, it rapidly **reverses their sedative and anxiolytic effects**, making it useful in overdose or to awaken patients post-procedure. *Alprazolam* - **Alprazolam** is a **benzodiazepine** itself, acting as a **GABA-A receptor agonist** rather than an antagonist. - It would **potentiate** the effects of other benzodiazepines, leading to increased sedation and respiratory depression, not reversal. *Propofol* - **Propofol** is an **intravenous anesthetic** that works by enhancing the effects of **GABA**, but it is not a specific benzodiazepine antagonist. - It would **deepen sedation** and anesthesia, which is the opposite of reversing benzodiazepine effects. *Naltrexone* - **Naltrexone** is a **mu-opioid receptor antagonist** used to block the effects of opioids in cases of overdose or addiction. - It has **no pharmacological effect** on the benzodiazepine receptor or its actions.
Explanation: ***Lorazepam*** - **Lorazepam** is the preferred first-line agent for status epilepticus due to its rapid onset of action and relatively long duration of anticonvulsant effect (12-24 hours), making it highly effective in stopping ongoing seizures. - Its **lipophilicity** allows it to quickly cross the blood-brain barrier while having less redistribution than diazepam, providing sustained seizure control. - Dose: **0.1 mg/kg IV** (typically 4 mg) administered at 2 mg/min. *Propofol* - **Propofol** is an anesthetic agent used in **refractory status epilepticus** when first and second-line agents have failed. - It carries risks of **hemodynamic instability**, **propofol infusion syndrome** with prolonged use, and requires ICU monitoring with intubation. - Reserved for third-line therapy, not appropriate as initial management. *Thiopentone* - **Thiopentone** is a barbiturate used for **refractory status epilepticus** as a third-line agent. - It has a longer half-life and recovery time compared to benzodiazepines, with significant **cardiovascular depression** and respiratory suppression. - Requires ICU setting with mechanical ventilation and hemodynamic support. *Phenytoin* - **Phenytoin** (or fosphenytoin) is a **second-line agent** used after benzodiazepines if seizures persist. - It has a **slower onset of action** (15-30 minutes) compared to benzodiazepines and requires cardiac monitoring due to risk of arrhythmias. - Loading dose: **20 mg/kg IV** at maximum rate of 50 mg/min to avoid cardiovascular complications.
Management of Anaphylaxis
Practice Questions
Drugs in Cardiac Arrest
Practice Questions
Status Epilepticus Management
Practice Questions
Acute Stroke Therapeutics
Practice Questions
Toxicological Emergencies
Practice Questions
Antidotes in Emergency Medicine
Practice Questions
Pain Management in Emergency
Practice Questions
Sedation and Paralysis in Emergency
Practice Questions
Drugs in Traumatic Emergencies
Practice Questions
Thrombolysis in Emergency Settings
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free